https://openbell.ai/ 2026-10-26T21:30:29.447Z hourly 1.0 https://openbell.ai/support 2026-10-26T21:30:29.447Z monthly 0.7 https://openbell.ai/privacy 2026-10-26T21:30:29.447Z monthly 0.5 https://openbell.ai/terms 2026-10-26T21:30:29.447Z monthly 0.5 https://openbell.ai/feed.json 2026-10-26T21:30:29.447Z hourly 0.8 https://openbell.ai/news/PSA:1793046727000 2026-10-26T20:32:07.000Z daily 0.9 https://cdn.brandfetch.io/PSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Public Storage Reports Q3 2026 Financial Results Public Storage reported third-quarter 2026 revenue of $1.37 billion, exceeding the FactSet consensus estimate of $1.34 billion. Funds From Operations (FFO) was $4.34 per share, above the $4.25 estimate. The company is the largest self-storage property operator in the United States. https://openbell.ai/news/WELL:1793046695000 2026-10-26T20:31:35.000Z daily 0.9 https://cdn.brandfetch.io/WELL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Welltower Inc. Reports Q3 2026 Financial Results Welltower reported Q3 2026 revenue of $3.72 billion, above the FactSet estimate of $3.64 billion. Normalized funds from operations were $1.67 per share, beating the $1.64 consensus estimate. The company raised its full-year 2026 normalized FFO outlook to $6.47–$6.53 per share, versus the prior FactSet estimate of $6.41. https://openbell.ai/news/MSFT:1793046685000 2026-10-26T20:31:25.000Z daily 0.9 https://cdn.brandfetch.io/MSFT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Microsoft Announces Voluntary Buyout Program for 60,000 Employees Microsoft is offering voluntary exit packages to 60,000 employees in the United States, Canada, India, and the United Kingdom, generally excluding data center, sales, and marketing teams. Chief People Officer Amy Coleman said the program is a new approach to workforce management as Microsoft accelerates investment in artificial intelligence. It follows a July reduction of 4,800 roles and a May buyout offer to 8,750 U.S. employees. https://openbell.ai/news/PFE:1793041323000 2026-10-26T19:02:03.000Z daily 0.9 https://cdn.brandfetch.io/PFE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Pfizer Receives FDA Approval for TALZENNA Combination Therapy Pfizer said the FDA approved TALZENNA (talazoparib) in combination with XTANDI to treat patients with mAPMN/S prostate cancer harboring HRR gene mutations. TALZENNA is an oral PARP inhibitor that blocks enzymes involved in DNA damage repair. The approval expands treatment options for this patient group and adds to Pfizer’s oncology portfolio; the article reports no financial figures or stock-price impact. https://openbell.ai/news/MIRM:1793037751000 2026-10-26T18:02:31.000Z daily 0.9 https://cdn.brandfetch.io/MIRM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mirum Pharmaceuticals Reports Positive Phase 2 PROGRESS Study Results for ATEBRIOZ in Children with FOP Mirum Pharmaceuticals reported positive 24-week results from the second cohort of its Phase 2 PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. Bone lesion volume decreased by 8.09 cm³ among treated patients, compared with a 9.14 cm³ increase with placebo; treated patients also showed improved joint mobility, no new lesions, and no new safety signals. Mirum plans to submit a supplemental New Drug Application to the FDA in the first half of 2027 to seek approval for use in this younger age group. https://openbell.ai/news/SOBO:1793037749000 2026-10-26T18:02:29.000Z daily 0.9 https://cdn.brandfetch.io/SOBO/w/400/h/400?c=1idopYfmtR7ZKg8QMud South Bow Corporation Reports Spring Quarter Profit Growth and Provides Prairie Connector Update South Bow Corporation reported spring-quarter profit of US$134 million, up nearly 40% from the same period last year. Its proposed Prairie Connector pipeline has secured customer commitments for 465,000 barrels per day over 20 years and would use existing infrastructure from the cancelled Keystone XL project to transport crude to U.S. markets. South Bow is targeting a final investment decision by mid-2027, subject to obtaining the required regulatory permits. https://openbell.ai/news/WCN:1793037741000 2026-10-26T18:02:21.000Z daily 0.9 https://cdn.brandfetch.io/WCN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Waste Connections Reports Q3 2026 Financial Results Waste Connections reported third-quarter 2026 results that exceeded analyst expectations for revenue and non-GAAP profit. Management cited core pricing, solid waste margin expansion, and improved landfill volumes as drivers of performance. The stock reached a 52-week high of $260.95 on the Toronto Stock Exchange on October 26, 2026. https://openbell.ai/news/CMI:1793037740000 2026-10-26T18:02:20.000Z daily 0.9 https://cdn.brandfetch.io/CMI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cummins Announces Multiyear Hyperscaler Supply Agreement and Raises 2026 Revenue Outlook Cummins CEO Jennifer Rumsey announced a multiyear supply agreement with a hyperscaler, backed by expanded manufacturing capacity. The company raised its 2026 revenue growth outlook to 10%–13%. Management also clarified the timing of upcoming EPA emissions regulations, anticipating a staggered engine rollout through 2027. https://openbell.ai/news/CORT:1793037738000 2026-10-26T18:02:18.000Z daily 0.9 https://cdn.brandfetch.io/CORT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Corcept Therapeutics Announces Positive Phase 2 BELLA Trial Results for Lifyorli Combination in Ovarian Cancer Corcept Therapeutics reported positive Phase 2 BELLA trial results for Lifyorli combined with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer. The regimen achieved median progression-free survival of 7.2 months and an objective response rate of 59%; 88% of patients were alive at the six-month overall-survival timepoint. The results mark a clinical update for Corcept’s oncology development program; the article did not report financial results or a stock-price reaction. https://openbell.ai/news/PEN:1793037733000 2026-10-26T18:02:13.000Z daily 0.9 https://cdn.brandfetch.io/PEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Penumbra, Inc. Announces Positive Clinical Results from BOLT-DVT Trial Penumbra reported positive results from its BOLT-DVT IDE clinical trial, with a 98% thrombus removal rate and a 3.1% major adverse event rate at 48 hours. At 30 days, 84.3% of treated patients were free of post-thrombotic syndrome; patients also reported immediate, sustained pain relief and improved quality of life on the VEINES-QOL measure. The article did not report financial results or a stock-price reaction. https://openbell.ai/news/JAZZ:1793037723000 2026-10-26T18:02:03.000Z daily 0.9 https://cdn.brandfetch.io/JAZZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jazz Pharmaceuticals' ZIIHERA Receives Regulatory Approvals for Biliary Tract Cancer Jazz Pharmaceuticals and its partners received U.S. accelerated approval and EU conditional marketing authorization for ZIIHERA (zanidatamab-hrii) for eligible patients with biliary tract cancer. The drug is licensed from Zymeworks. Jazz is also conducting the Phase 3 HERIZON-GEA-01 trial, testing ZIIHERA with chemotherapy as a first-line treatment for advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The article reports no financial results or stock-price impact.